DCTD's Translational Research Program Announces Fiscal Year 2024 SPORE Grantees
- Posted:
The Translational Research Program announced its successfully competed FY2024 Specialized Programs of Research Excellence (SPORE) grantees.
The SPORE program uses the P50 and U54 grant funding mechanisms to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites.
There are now 56 funded SPOREs located at academic centers in 21 states. Read about each SPORE project by accessing the Principal Investigators' links in the table below.
| Principal Investigator | Institution | Cancer Type |
| Tracy T. Batchelor | Brigham and Women's Hospital | Brain* |
| Frederick F. Lang; Juan Fueyo | University of Texas MD Anderson Cancer Center | Brain* |
| Charles M. Perou; Lisa A. Carey | University of North Carolina, Chapel Hill | Breast* |
| T-C Wu; Warner King Huh | Johns Hopkins University | Cervical* |
| Ulrike Peters; Christopher Li; Timothy Thomas | Fred Hutchinson Cancer Center | Colorectal |
| Daniel C. Link | Washington University, St. Louis | Leukemia* |
| Mark A. McNiven; Lewis R. Roberts | Mayo Clinic, Rochester | Liver* |
| Ming-IE Shih; Ronny I. Drapkin | Johns Hopkins University | Ovarian* |
| Felix Yi-Chung Feng; Eric J. Small | University of California, San Francisco | Prostate |
| Samuel R. Denmeade; Shawn Lupold | Johns Hopkins University | Prostate |
| Samuel Singer | Memorial Sloan Kettering Cancer Center | Sarcoma* |
*Grant Renewal